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Background : Coronavirus disease 2019 (COVID-19) has affected people all around the world in varying degrees 
of severity, causing death. The global case fatality rate (CFR) due to COVID-19 was 2.2 % as of January 1st, 2021. 
The CFR in the Kediri district is 7.7%, which is higher than the Nasional CFR of 3%. In COVID-19, we looked at 
high D-dimer as one of the predictors of in-hospital mortality.
Objectives : The goal of this study was to find a link between D-dimer levels and all-cause in-hospital mortality in 
COVID-19 patients, as well as to define the best cut-off point.
Methods : A single-center cross-sectional study was conducted. From March to December 2020, 185 COVID-19 
patients treated at Kediri General Hospital who were confirmed positive by RT-PCR matched the eligibility 
criteria. The levels of D-dimer were divided into two groups: those above and those below the cutoff point. We 
analyzed 4 cut of points, D-dimer ≥ 0.5 µg/ml, D-dimer ≥ 2 µg/ml, D-dimer ≥ 3 µg/ml, and D-dimer ≥ 4 µg/ml. 
The primary endpoint was all-cause in-hospital mortality. Data were collected retrospectively and processed 
using SPSS version 25.0.
Results : During hospitalization, 45 patients (24.3%) were died. Elevated D-dimer ≥ 4 µg/ml was statistically 
significant associated with all-cause inhospital mortality (adjusted odds ratio [OR] 3.46;  95% confidence interval 
[CI] = 1.41 – 8.49, p = 0.007), with a sensitivity of 82.1% and a specificity of 42.2% ( area under curve [AUC] 
= 0.628; 95% CI = 0.527 – 0.728; p = 0.012).
Conclusion : Elevated D-dimer levels were associated with all-cause in-hospital mortality. In our study, the 
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COVID-19.
 Coronavirus disease 2019 (COVID-19) has spread among 
humans worldwide and infected over 80 million people as of January 
1st, 2021.1 WHO data on January 1st, 2021 shows as many as 1.8 
million confirmed deaths, case fatality rate 2.2%. There are 221 
affected countries and 180 local transmission countries, one of which is 
Indonesia. Data compiled by the Ministry of Health of the Republic of 
Indonesia until January 1st, 2021, states as many as 743. A total of 198 
confirmed cases, with a case fatality rate of 3%, is higher than the 
global mortality rate.2 Local transmission has occurred in Kediri, East 
Java, Indonesia. The case fatality rate in the Kediri district is 7,7% (189 
out of 2448 confirmed cases), higher than the CFR in East Java which 
is around 6.93% (5900 deaths out of 85039 confirmed cases).3,4 Based 
on these data, it is necessary to evaluate what causes the high mortality 
rate in Kediri district, especially in Kediri District Hospital (RSUD 
Kabupaten Kediri), as one of the leading referral hospitals for 
COVID-19 in the Kediri district area.
 COVID-19 infection without symptoms, mild COVID-19
infection, moderate COVID-19 infection, severe COVID-19 infection, 
and critically ill COVID-19 infection COVID-19 infection can be found 
at a variety of phases.5 Patients with severe COVID-19 are at risk for 
coagulopathy, including DIC and hypercoagulable condition, in 
addition to respiratory failure.6,7 According to a recent meta-analysis by 
Boonyawat et al., the incidence of venous thromboembolism (VTE) 
among COVID-19 patients in ICU settings was 28%, while it was 10% 
in non-ICU settings.8 D-dimers are protein fragments formed by fibrin 
clot breakdown that can be exploited as biomarkers for suspected VTE. 
We aimed to figure out the link between high D-dimer levels and 
in-hospital mortality in COVID-19 patients, as well as the optimum 
D-dimer cut-off value for predicting death.
2. Methods
2.1 Study Design
 From the beginning of the pandemic in March through 
December 2020, a single-center retrospective investigation was under-
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hospitalized patients over the age of 18 who had a positive COVID-19 
real-time polymerase chain reaction.
2.2 Ethical approval
 Our study was a retrospective medical record review of a 
COVID-19 patient database. This study has received approval from the 
local ethics of Kediri General Hospital. 
2.3 Participants and eligibility criteria
 Adult patients over 18 years old with laboratory results 
confirmed COVID-19 by RT-PCR method, mild to severe symptoms 
hospitalized at Kediri General Hospital, as one of the national referral 
hospitals for COVID-19, between March and December 2020 were 
included. Patients who had D-dimer results were included in the study. 
Exclusion criteria for this study were patients who were not examined 
for D-dimer levels, pregnant women, and patients whose outcome was 
unknown until the end of the study period. The clinical diagnosis of 
COVID-19 was made according to recent WHO guidelines. The 
endpoint was all-cause mortality during hospitalization. Figure 1 shows 
a flowchart of the study.
2.4 Measurement
 Demographic data, history of present illness, past medical 
history, physical examination, blood oxygen saturation (SaO2) at 
admission, ECG, blood laboratory test collected within 24 hours after 
admission (hemoglobin, leucocyte, thrombocyte, D-Dimer), and Chest 
X-Ray. The D-dimer level was tested using an immunochromatography 
assay (Wondfo). The outcomes were collected from medical records 
and analyzed. Severe illness COVID-19 patients have Sp02 < 94 % on 
room air, Pa/FiO2 < 300 mmHg, respiratory rate more than 30 breaths 
per minute, or pulmonary infiltrates more than 50 %.(5) D-dimer levels 
were categorized into two groups, above and below the cut of point. We 
analyzed 4 cut of points, D-dimer ≥ 0.5 µg/ml, D-dimer ≥ 2 µg/ml, 
D-dimer ≥ 3 µg/ml, and D-dimer ≥ 4 µg/ml. The outcome was divided 
into two groups, survivor and in-hospital mortality.
2.5 Statistical analysis
 Data were processed using SPSS software 25.0 for windows, 
IBM. Univariate analysis was performed for baseline characteristics. 
The normal distribution of quantitative variables was expressed as 
mean ± standard deviation (SD), while quantitative variables with 
abnormal distribution were represented as median (IQR). Categorical 
variables were presented as number and proportions (%). Categorical 
bivariate analysis was performed with the chi-square (χ2) or as an 
alternative Fisher’s exact test. Numerical data were tested for normal 
and abnormal data distribution, then analyzed using an independent 
T-test and Mann Whitney, respectively. The variance was tested with 
Lavene’s test. Kolmogorov-Smirnov tested data distribution. P <0.05 is 
used to denote significance for the primary outcome. All results will be 
presented in odds ratio (OR) format with a 95% confidence interval 
(CI). The backward approach of logistic regression was used to do 
multivariate analysis. Cut-off point, specificity, and sensitivity were 
determined using the receiver operating characteristic (ROC) curve and 
its area under the curve (AUC).
3. Results
3.1 Patients selection
 Of the 262 patients who were confirmed RT-PCR COVID-19 
from March to December 2020, 165 patients met the inclusion criteria. 
Patients hospitalized with severe to critical illness were 46.7 % 
(77/165).
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Figure 1. Study flowchart. 
COVID-19 = coronavirus disease 2019; ECG = electrocardiogram.
3.2 Baseline characteristics
 The median age was 54.1 years, ranging from 19 to 87 years. 
The number of elderly patients (≥ 60 years) was 28.5 % (47/165), and 
48.5 % (80/165) were men. In general, the mean length of stay (LOS) 
was 9.7 ± 4.4 days. The most common symptom was cough and 
dyspnea, about 62.4% (103/165) and followed by fever 40 % 
(66/165). A history of illness often encountered is diabetes mellitus 
(26.1 %) and hypertension (22.4 %). Comparison of baseline charac-
teristics, laboratory results, and X-rays on admission COVID-19 patients 
based on survival status is shown in table 1. 
3.3 Main findings
 The number of patients who died during hospitalization was 
About 27.3% of patients. Patients who died were statistically signifi-
cantly older than those who survived (59 ± 17 vs. 54.5 ± 15 years; P 
<0.001). The proportion of elderly patients (over 60 years old) who 
died was higher (38.3% vs. 22.9%; P = 0.045). Systolic (130 ± 27 vs. 
130 ± 31 mmHg; P = 0.854) and diastolic (70 ± 20 vs. 80 ± 20 
mmHg; P = 0.259) blood pressure were not different between both 
groups. Heart rate patients who died was significantly higher (100 ± 
29 vs. 93 ± 15; P-value = 0.002). 
 We analyzed several cut-of-point D-dimer values based on 
previous studies. A study conducted by Huang stated that D-dimer ≥ 
0.5 µg/ml was significant in predicting inhospital mortality COVID-19 
patients. (9) Several studies reported D-dimer level ≥ 2 µg/ml had 
higher mortality in COVID-19 patients.10-12 Another research classified 
D-dimer values into groups (D-dimer <2x upper limit of normal (ULN), 
2-3.9x ULN, 4-7.9x ULN, and >8x ULN.13 In our study, patients with 
D-dimer value ≥ 0.5 µg/ml did not significantly differ in mortality (OR 
= 0.94;  95% CI = 0.42 – 2.10; p = 0.881). Patients who had D-dimer 
value ≥ 2 µg/ml had increased all-cause inhopital mortality (OR = 
2.51; 95%CI = 1.23 – 5.13; p = 0.100). The proportion of deaths of 
patients with D-dimer ≥ 3 µg/ml was higher than patients who had 
D-dimer < 3 µg/ml (46.5 % vs. 20.5 %) with p value 0.010 (OR = 3.37; 
95%CI = 1.61 – 7.09). About 48.7% of death happened to patients with 
D-dimer level ≥ 4 µg/ml, and statistically proven to predict all-cause 
inhospital mortality in COVID-19 patients (OR = 3.65; 95%CI = 1.71 –
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Table 1. Baseline characteristics.
Variables 
Age (year) 
≥ 60 years old  















Decreased of consciousness 
History of illness 
Diabetes mellitus 
Hypertension 




Chronic kidney disease 
Stroke 
Systolic blood pressure (mmHg) 
Diastolic blood pressure (mmHg) 
Heart rate (bpm) 
SpO2 < 94% 
Febrile (T >38℃) 
Output 
In-hospital mortality 
(n = 45) 
59 ± 17 
18 (38.3 %) 
27 (22.9 %) 
 
19 (23.8 %) 
26 (30.6 %) 
 
19 (28.8 %) 
27 (26.2 %) 
36 (35.0 %) 
3 (15.8 %) 
7 (26.9 %) 
18 (24.7 %) 
1 (10.0 %) 
22 (29.7 %) 
2 (5.7 %) 
0 (0 %) 
6 (33.3 %) 
 
15 (34.9 %) 
6 (16.2 %) 
1 (33.3 %) 
6 (66.7 %) 
0 (0 %) 
0 (0 %) 
1 (100 %) 
5 (71.4 %) 
130 ± 27 
78 ± 20 
100 ± 29 
26 (38.2 %) 
2 (16.7 %) 
Survivor 
(n = 120) 
54.5 ± 15 
29 (61.7 %) 
91 (77.1 %) 
 
61 (76.3 %) 
59 (69.4 %) 
 
47 (71.2 %) 
76 (73.8 %) 
67 (65.0 %) 
16 (84.2 %) 
19 (73.1 %) 
55 (75.3 %) 
9 (90.0 %) 
52 (70.3 %) 




28 (65.1 %) 
31 (83.8 %) 
2 (66.7 %) 
3 (33.3 %) 
1 (100 %) 
1 (100 %) 
0 (0 %) 
2 (28.6 %) 
130 ± 31 
80 ± 20 
93 ± 15 
42 (61.8 %) 
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7.00; p = 0.001). Multivariate analysis using regression logistic with 
backward method shows D-dimer ≥ 4 µg/ml significantly increase 
inhospital mortality (OR = 3.46; 95%CI = 1.41 – 8.49; p = 0.007). 
Figure 2 decribes the discrimination of all-cause inhospital mortality 
using cut of point D-dimer ≥ 4 µg/ml (AUC = 0.622; 95% CI = 0.523 
– 0.721; p = 0.014) with a specificity of 42.2% and a sensitivity of 
82.1%.
4. Discussion
 D-dimer is a fibrin degradation product that can be formed in 
several medical conditions. An increase in D-dimer level above 0.5 
µg/ml can occur in infection, cancer, pregnancy, venous thromboembo-
lism, and disseminated intravascular coagulation (DIC).14 Coagulopa-
thy has been reported in COVID-19 patients leading to hypercoagulabil-
ities such as elevated D-dimer, fibrinogen, factor VIII, and sepsis-in-
duced coagulopathy score (SIC score).15
17
 An intersection between inflammation and coagulation 
factors is thought to be the mechanism behind hypercoagulability. A 
cytokine storm occurs when COVID-19 infection causes a rise in pro-in-
flammatory cytokines such as G-CSF, IP-10, IL-2, IL-6, IL-7, IL-10, 
MCP-1, MIP-1A, and TNF-α. This cytokine storm triggers an increase in 
inflammatory markers such as CRP, fibrinogen, LDH. Elevated IL-6 
levels in the blood can induce tissue factor expression and initiate 
coagulation activation and thrombin formation. SARS-CoV-2 binds to 
ACE-2 receptors in the vascular endothelium, causing direct or indirect 
endothelial dysfunction, leading to thrombosis.16
 International Society on Thrombosis and Haemostasis 
recommendations in enforcing VTE diagnosis for hospitalized 
COVID-19 patients, especially those critically ill, are to do risk stratifica-
tion and check on D-dimer level. Imaging examinations are not recom-
mended for routine diagnosis to prevent COVID-19 transmission. 
Elevated D-dimer above 1.5 µg/ml has a specificity of 88.5 % and a
Decreased of consciousness 5 (100 %) 0 (0 %) 0.001 
History of illness  
Diabetes mellitus 
Hypertension 




Chronic kidney disease 
Stroke 
Systolic blood pressure (mmHg) 
Diastolic blood pressure (mmHg) 
Heart rate (bpm) 
SpO2 < 94% 
Febrile (T >38℃) 





D-dimer ≥ 0.5 µg/ml 
D-dimer ≥ 2 µg/ml 
D-dimer ≥ 3 µg/ml 
D-dimer ≥ 4 µg/ml 
Chest X-Ray Pneumonia 
Length of stay 
15 (34.9 %) 
6 (16.2 %) 
1 (33.3 %) 
6 (66.7 %) 
0 (0 %) 
0 (0 %) 
1 (100 %) 
5 (71.4 %) 
130 ± 27 
78 ± 20 
100 ± 29 
26 (38.2 %) 
2 (16.7 %) 
5 (100 %) 
13.4 ± 3 
10.3 ± 8.4 
225.5 ± 147.3 
29 (37.7 %) 
34 (27.0 %) 
21 (40.4 %) 
20 (46.5 %) 
19 (48.7%) 
41 (31.3 %) 
7 ± 7 
 
28 (65.1 %) 
31 (83.8 %) 
2 (66.7 %) 
3 (33.3 %) 
1 (100 %) 
1 (100 %) 
0 (0 %) 
2 (28.6 %) 
130 ± 31 
80 ± 20 
93 ± 15 
42 (61.8 %) 
10 (83.3 %) 
0 (0 %) 
13.9 ± 2 
8.4 ± 4.4 
268 ± 179.3 
48 (62.3 %) 
92 (73.0 %) 
31 (59.6 %) 
23 (53.5 %) 
20 (51.3%) 
90 (68.7 %) 


























COPD = chronic obstructive pulmonary disease; SpO2 = peripheral oxygen saturation. 
Table 3. Mean Comparison of β-blocker to Physical Score and Emotional Score
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sensitivity of 85%. Whereas D-dimer above 4 µg/ml has a poor 
outcome.17
 The cut-off value for D-dimer levels that potentially predict 
all-cause in-hospital mortality is compared in our study. In our study, 
patients with D-dimer level ≥ 4 µg/ml statistically significant predicts 
all-cause in-hospital mortality in COVID-19 patients (OR = 3.65; 
95%CI = 1.71 – 7.83; p = 0.001). These results are consistent with 
research conducted by Short et al.13 Short et al. classified D-dimers into 
four groups: D-dimer <2x upper limit of normal (ULN), 2-3.9x ULN, 
4-7.9x ULN, and >8x ULN, with the conclusion that a higher amount of 
D-dimer is linked to an increased risk of death.
 Many studies have reported the optimal D-dimer cut-off 
point in predicting mortality COVID-19 patients is 2 µg/ml.9-11
18
Meanwhile in our study, COVID-19 patients who had D-dimer value ≥ 
2 µg/ml had increased all-cause inhopital mortality (OR = 2.51; 95%CI 
= 1.23 – 5.13; p = 0.10). But, multivariate analysis using regression 
logistic with backward method shows D-dimer ≥ 4 µg/ml significantly 
increase inhospital mortality (OR = 3.46; 95%CI = 1.41 – 8.49; p = 
0.007). The AUC value of D-dimer ≥ 4 µg/ml shows discrimination 
(AUC = 0.628; 95% CI = 0.527 – 0.728; p = 0.012).
 This study has several limitations. This study was a 
single-center cross-sectional study. The sample size was relatively 
small. Not all confirmed COVID-19 patients have D-Dimer levels 
checked. The D-dimer examination was only done on admission within 
24 hours, so we did not know when the patients had worsening 
conditions. The D-dimer value in our laboratory machines has a lower 
limit of 0.1 µg/ml and an upper limit of 10 µg/ml. If a patient has a 
D-dimer value below 0.1 µg/ml or above 10 µg/ml, we can only catego-
rize it into categorical data. Numerical data were not fully available, so 
the ROC curve could not be processed to assess the effective cut-off 
point D-dimer value.
5. Conclusion
 Elevated D-dimer levels were associated with all-cause 
in-hospital mortality. In our study, the optimal cut of point D-dimer 
value was 4 µg/ml.
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Bivariate analysis Multivariate analysis 
Elderly, age ≥ 60 years old 
SpO2 < 94% 
Decrease of consciousness 
Severe illness 
Chest X Ray Pneumonia 
D-dimer ≥ 0.5 µg/ml 
D-dimer ≥ 2 µg/ml 
D-dimer ≥ 3 µg/ml 











OR (95% CI) 
2.09 (1.01 – 4.33) 
2.54 (1.26 – 5.12) 
4.00 (3.06 – 5.23) 
2.72 (1.34 – 5.54) 
3.30 (1.09 – 10.01) 
0.94 (0.42 – 2.10) 
2.51 (1.23 – 5.13) 
3.37 (1.61 – 7.09) 











OR (95% CI) 
2.26 (1.004 – 5.09) 
- 
20.58 (1.58 – 267.91) 
2.40 (1.09 – 5.26) 
2.84 (0.87 – 9.27) 
0.43 (0.17 – 1.10) 
- 
- 
3.46 (1.41 – 8.49) 
Table 2. Bivariate and multivariate analysis of categoric variables associated with higher mortality.
CI = confidence interval SpO2 = peripheral oxygen saturation; OR = Odds ratio.
Figure 2. Receiver operating characteristics curve of D-dimer cut-off 
point.
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